Drug Type Small molecule drug |
Synonyms (+-)-N,N-Diethyl-N'-((3R*,4aR*,10aS*)-1,2,3,4,4a,5,10,10a-octahydro-6-hydroxy-1-propylbenzo(g)quinolin-3-yl)sulfamide, Norprolac, Quinagolide + [5] |
Target |
Mechanism D2 receptor agonists(Dopamine D2 receptor agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date ZA (24 Sep 1997), |
Regulation- |
Molecular FormulaC20H34ClN3O3S |
InChIKeyDVLKVIJLALMCBQ-PIULNQQYSA-N |
CAS Registry94424-50-7 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | Quinagolide Hydrochloride |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Hyperprolactinemia | ZA | 24 Sep 1997 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Adenomyosis | Phase 2 | DK | 19 Aug 2019 | |
Adenomyosis | Phase 2 | DE | 19 Aug 2019 | |
Adenomyosis | Phase 2 | IT | 19 Aug 2019 | |
Adenomyosis | Phase 2 | PL | 19 Aug 2019 | |
Endometriosis | Phase 2 | DK | 21 Jun 2019 | |
Endometriosis | Phase 2 | DE | 21 Jun 2019 | |
Endometriosis | Phase 2 | IT | 21 Jun 2019 | |
Endometriosis | Phase 2 | PL | 21 Jun 2019 | |
Pain | Phase 2 | US | 26 Dec 2018 | |
Ovarian Hyperstimulation Syndrome | Phase 2 | ES | 01 Jun 2006 |
Phase 2 | 67 | (Quinagolide 1080 µg) | rlajjoukgr(uvlpzpmkez) = jyingwtnce vpdrejjmug (vioroalnti, yrngphhrsz - xljkcgjkqa) View more | - | 07 Sep 2022 | ||
Placebo (Placebo) | rlajjoukgr(uvlpzpmkez) = nmufbtelki vpdrejjmug (vioroalnti, rbaqzfcshm - mpbxxshjft) View more | ||||||
Not Applicable | 9 | burczgxoof(umrflbfbti) = bmqzgarsoy oktmaqfnhf (jxzzppupva ) | - | 01 Mar 2011 |